Modality
Small Molecule
MOA
JAK1i
Target
IL-23
Pathway
mTOR
Fabry
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
Jan 2020
→ Aug 2027
Phase 2Current
NCT04030462
2,415 pts·Fabry
2020-01→2027-08·Recruiting
2,415 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-241.4y awayPh3 Readout· Fabry
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-08-24 · 1.4y away
Fabry
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04030462 | Phase 2/3 | Fabry | Recruiting | 2415 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 |